CNS Pharmaceuticals, Inc. (CNSP) stock
CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.15+0.67 (+19.25%)
Close on Nov 17, 2026Market cap $6.07MP/E –Yield –
CNS Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
CNS Pharmaceuticals's cash was $19.99M at Jun 30, 2026. For fiscal 2025 it was $7.20M, up 11.5% from the year before. The highest annual figure on record is $14.04M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.20M | +11.5% |
| FY2024 | Dec 31, 2024 | $6.46M | +1077.5% |
| FY2023 | Dec 31, 2023 | $548.72K | -94.5% |
| FY2022 | Dec 31, 2022 | $10.06M | +100.9% |
| FY2021 | Dec 31, 2021 | $5.00M | -64.4% |
| FY2020 | Dec 31, 2020 | $14.04M | +93.9% |
| FY2019 | Dec 31, 2019 | $7.24M | +1204.4% |
| FY2018 | Dec 31, 2018 | $555.13K | +402.2% |
| FY2017 | Dec 31, 2017 | $110.54K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.99M | +64.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.95M | -77.4% |
| Q4 FY2025 | Dec 31, 2025 | $7.20M | +11.5% |
| Q3 FY2025 | Sep 30, 2025 | $9.86M | +41.5% |
| Q2 FY2025 | Jun 30, 2025 | $12.13M | +713.2% |
| Q1 FY2025 | Mar 31, 2025 | $13.05M | +1500.5% |
| Q4 FY2024 | Dec 31, 2024 | $6.46M | +1077.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.97M | +666.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.49M | -65.1% |
| Q1 FY2024 | Mar 31, 2024 | $815.23K | -84.0% |
| Q4 FY2023 | Dec 31, 2023 | $548.72K | -94.5% |
| Q3 FY2023 | Sep 30, 2023 | $909.55K | -87.1% |
| Q2 FY2023 | Jun 30, 2023 | $4.28M | -52.2% |
| Q1 FY2023 | Mar 31, 2023 | $5.11M | -58.9% |
| Q4 FY2022 | Dec 31, 2022 | $10.06M | +100.9% |
| Q3 FY2022 | Sep 30, 2022 | $7.03M | -15.6% |
| Q2 FY2022 | Jun 30, 2022 | $8.96M | +30.1% |
| Q1 FY2022 | Mar 31, 2022 | $12.44M | +12.3% |
| Q4 FY2021 | Dec 31, 2021 | $5.00M | -64.4% |
| Q3 FY2021 | Sep 30, 2021 | $8.33M | +537.0% |
| Q2 FY2021 | Jun 30, 2021 | $6.89M | +162.2% |
| Q1 FY2021 | Mar 31, 2021 | $11.08M | +105.9% |
| Q4 FY2020 | Dec 31, 2020 | $14.04M | +93.9% |
| Q3 FY2020 | Sep 30, 2020 | $1.31M | +107.4% |
| Q2 FY2020 | Jun 30, 2020 | $2.63M | +187.9% |
| Q1 FY2020 | Mar 31, 2020 | $5.38M | +3370.4% |
| Q4 FY2019 | Dec 31, 2019 | $7.24M | +1204.4% |
| Q3 FY2019 | Sep 30, 2019 | $630.11K | -11.1% |
| Q2 FY2019 | Jun 30, 2019 | $911.93K | +725.0% |
| Q1 FY2019 | Mar 31, 2019 | $155.02K | – |
| Q4 FY2018 | Dec 31, 2018 | $555.13K | – |
| Q3 FY2018 | Sep 30, 2018 | $708.63K | – |
| Q4 FY2017 | Dec 31, 2017 | $110.54K | – |
See a number that looks wrong?